Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Navidea Biopharmaceuticals's Equity-to-Asset or its related term are showing as below:
NAVBQ's Equity-to-Asset is not ranked *
in the Biotechnology industry.
Industry Median: 0.69 * Ranked among companies with meaningful Equity-to-Asset only.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Navidea Biopharmaceuticals Equity-to-Asset Related Terms
Navidea Biopharmaceuticals Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NAVBQ vs PKBO, RSPI, ATRX: Equity-to-Asset Comparison
For the Biotechnology subindustry, Navidea Biopharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Navidea Biopharmaceuticals Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Navidea Biopharmaceuticals's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Navidea Biopharmaceuticals's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Navidea Biopharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Navidea Biopharmaceuticals (NAVBQ) has a Equity-to-Asset of -0.57 as of Sep. 2023. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Navidea Biopharmaceuticals and its competitors.
Is Navidea Biopharmaceuticals' Equity-to-Asset too high?
Navidea Biopharmaceuticals' current Equity-to-Asset is -0.57. Overall, Navidea Biopharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Navidea Biopharmaceuticals' Equity-to-Asset compare to PKBO and RSPI?
Navidea Biopharmaceuticals' Equity-to-Asset of -0.57 can be compared against companies in the Biotechnology industry. The industry median Equity-to-Asset is 0.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.69, based on 1,414 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Navidea Biopharmaceuticals and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Navidea Biopharmaceuticals's current Equity-to-Asset is -0.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Navidea Biopharmaceuticals stock overvalued right now?
Navidea Biopharmaceuticals (NAVBQ) has a current Equity-to-Asset of -0.57. The current Equity-to-Asset is -0.57. Navidea Biopharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Navidea Biopharmaceuticals (NAVBQ), the current Equity-to-Asset is -0.57 as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Navidea Biopharmaceuticals Inc is a biotechnology company specializied in precision medicine. Its products, precision immunodiagnostic agents and immunotherapeutic products are designed to assist in the identification of undetected diseases and to improve targeted treatment. The company's platform, known as Manocept technology, aims to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. One of the company's products is Lymphoseek, a radioactive diagnostic agent indicated to locate lymph nodes.
16GF Score
Get the complete analysis for NAVBQ
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NAVBQ has been successfully added to your 
